Avacta Group plc (LSE:AVCT), the AIM-quoted oncology drug developer, used a presentation at a US cancer conference on 25 September 2026 to set out further data on AVA6103, the second drug built on its pre|CISION platform. The question is why the company is emphasising this asset, and what the data show.

A clinical-stage oncology platform

Avacta (LSE:AVCT) describes itself as a clinical-stage life sciences company developing targeted cancer therapies. Its pre|CISION technology attaches a potent chemotherapy payload to a peptide that is cleaved by fibroblast activation protein (FAP), an enzyme found in high concentrations in the tumour microenvironment. The design aims to release the drug mainly inside tumours, limiting exposure of healthy tissue. The group sold its diagnostics businesses during 2025, leaving it focused on therapeutics. Its lead asset, faridoxorubicin (AVA6000), carries a doxorubicin payload, while AVA6103 (FAP-Exd) delivers exatecan, a topoisomerase inhibitor.

What the 25 September announcement said

According to its RNS of 25 September 2026, Avacta presented preclinical work on AVA6103 at the American Association for Cancer Research conference on pancreatic cancer in San Diego. In patient-derived xenograft mouse models, a dose-dense regimen given every two weeks produced durable complete and partial tumour responses. The company reported high FAP expression in pancreatic cancer tissue, with cancer-associated fibroblasts positioned close to blood vessels and tumour cells. Chief executive Christina Coughlin said the data "underscore the significant potential of AVA6103 in addressing the challenges of pancreatic cancer."

The release built on a 16 September update from the Phase 1 FOCUS-01 trial. Covering 19 patients across the first three dose levels, Avacta reported a "clean safety profile", no neutropenia, and tolerance of a payload dose about 50% above the maximum tolerated dose of conventional exatecan. It said pharmacokinetic data showed exatecan being released over several days. Further data are scheduled for the ESMO Congress in October, and first efficacy data are expected in the first half of 2027.

Finances and funding

Avacta remains loss-making. Its unaudited preliminary results for 2025, published on 19 May 2026, showed continuing Revenue of £0.113 million, an operating loss of £30.7 million and a loss for the year of £38.6 million, narrower than £52.8 million in 2024. Cash stood at £16.9 million at 31 December 2025. The company raised £10 million in March 2026 and a further £9 million at 70p per share in June 2026, the latter largely from one cornerstone institution.

A Convertible Bond remains a feature of the balance sheet. On 4 September 2026 Avacta paid an accelerated instalment of £2.613 million in cash, and said £12.0 million of principal remained outstanding. Cash settlement avoided issuing new shares.

On the lead programme, Avacta said on 25 June 2026 that the US Food and Drug Administration had agreed a single pivotal trial design for faridoxorubicin in salivary gland cancer, with progression-free survival as the primary endpoint. The company added that it would progress the drug further only with the support of a partner.

Risks and what to watch

Most of the new AVA6103 evidence is preclinical or early safety and pharmacokinetic data; no efficacy readout from FOCUS-01 has yet been published. Early-stage oncology results often Fail to translate into later trials. Funding is a continuing uncertainty: the preliminary results pointed to cash runway into early 2027, and subsequent fundraises and bond payments will change that picture. Securing a partner for faridoxorubicin, the ESMO presentation and the 2027 efficacy readout are the key milestones.

Conclusion

Avacta is highlighting AVA6103 because the company regards it as validation of the pre|CISION approach across a second payload, with early safety and pharmacokinetic data it describes as consistent with preclinical models. The 25 September data strengthen that scientific narrative, but clinical efficacy, partnering and financing remain the tests still ahead.